Cargando…
Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
Sickle cell disease, despite its recognition as a severely debilitating genetic condition affecting hundreds of thousands of neonates throughout the world each year, was not a target of pharmaceutical research focus for most of its 100-year existence in the medical consciousness. This has changed in...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983433/ https://www.ncbi.nlm.nih.gov/pubmed/33796238 http://dx.doi.org/10.1177/20406207211001136 |